Joint Formulary & PAD

Flupentixol - Schizophrenia and other psychoses

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Tablets
Associated Icons :
SPC
Restrictions / Comments :
Important

Initiation by a SABP specialist and stabilisation for a minimum of 3 months before any request to transfer prescribing responsibility.

 

Status 2

Amber
Formulations :
  • Depot injection
Associated Icons :
SPC
Restrictions / Comments :
Important

Flupenthixol decanoate - administration under the shared-care LCS when prescribed in Primary Care.

See shared-care document below

Documents :
 
 

Status 3

Red
Formulations :
  • Depot injection
Associated Icons :
SPC
Restrictions / Comments :
Important

Flupenthixol decanoate - where there is no LCS in place, the prescribing responsibility remains with SABP.

Secondary Care may prescribe for in-patients (on the instruction of a SABP specialist) and prescribing continued by SABP after discharge.

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Flupentixol
Indication :
Schizophrenia and other psychoses
Group Name :
Keywords :
antipsychotic depot injections, LAI, depot antipsychotics
Brand Names Include :
Fluanxol, Depixol
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1
Traffic Light Entries :
3

Other Indications

Below are listed other indications that Flupentixol is used to treat.

  • No records returned.

Committee Recommendations (0)

  • No records returned.